Marjorie Zauderer
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Marjorie Zauderer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:56 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT02639767 · Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural MesotheliomaMemorial Sloan Kettering Cancer Center · withdrawn · Malignant Pleural Mesothelioma · principal investigator
- N/ANCT01773655 · Clinical and Histopathologic Characteristics of BAP1 MutationsMemorial Sloan Kettering Cancer Center · completed · Malignant Pleural Mesothelioma (MPM), Choroidal Nevus, Primary Uveal Melanoma (UM) · principal investigator
- Ph2NCT01265433 · Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality TherapySellas Life Sciences Group · completed · Malignant Pleural Mesothelioma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesotheliomaR01CA235667 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2019 to 2023 · $712,796 awarded in 2023Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:56 UTC. The ranking covers the 200 most relevant of 20 PubMed records, and a shared surname and initials can bring in a namesake. All 20 on PubMed
- A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.Cancer Discov · 2021537 citationsRCR 26.3
- 142 citationsRCR 5.5
- EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.Lancet Oncol · 2022119 citationsRCR 7.7
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.Clin Cancer Res · 2016118 citationsRCR 3.6
- 65 citationsRCR 13.1
- Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.JAMA Oncol · 202456 citationsRCR 7.1
- Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.Clin Cancer Res · 201655 citationsRCR 1.8
- A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.Clin Cancer Res · 201752 citationsRCR 1.3
- Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.Nat Med · 202252 citationsRCR 3.9
- Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis.Int J Radiat Oncol Biol Phys · 202333 citationsRCR 4.4